Moderate levels of SCFAs boost anti-tumor immunity by adjusting the immune microenvironment, enhancing the effectiveness of anti-PD-1/PD-L1 treatment. Excessively high SCFA levels may increase immune tolerance. Here, CD274 is linked to neoplasm.